Differential functionality of fluoropyrimidine nucleosides for safe cancer therapy

Tim Holzinger[1,3], Julia Frei[1,3], Natalia Teresa Jarzebska[1,2], Hans-Dietmar Beer[1,3], Thomas M. Kündig[1,3], Steve Pascolo[1,3,&], Severin Läuchli[1,3,&], Mark Mellett[1,3,&]

[1] Department of Dermatology, University Hospital Zürich (USZ), University of Zürich (UZH),
Raemistrasse 100, 8091 Zürich
[2] Faculty of Science, University of Zürich, 8091 Zürich, Switzerland
[3] Faculty of Medicine, University of Zürich, 8091 Zürich, Switzerland
[&] Authors contributed equally
* Correspondence: Steve.Pascolo@usz.ch, Mark.Mellett@usz.ch



Supplementary figure 1: Chemical structures of the drugs used in the experiments. A: 5FC, B: 5FU, C: FCyd, D: FUrd, E: FdCyd, F: FdUrd



Supplementary Figure 2: Thymidine and uridine rescue data, cell viability assay in HeLa (A, B) and HEK293 (C, D) cells. Percentage cell viability in comparison to NT after 3 days of incubation at 37°C. Data indicated by mean and 95% CI, as well as separate data points. Experiment was done in triplicates. Cells received their respective treatment (drug and/or uridine/thymidine) on day 0. Thy: thymidine, Urd: uridine, uridine concentration: 1 mmol/l, thymidine concentration: 80 µmol/l, drugs: see legend. Drug concentrations added with the goal of achieving CC_{80}. HeLa: 5-Fluorocytidine: 0.25 µg/ml, 2'-deoxy-5-Fluorocytidine: 2 µg/ml, 5-Fluorouridine: 0.25 µg/ml, 2'-deoxy-5-Fluorouridine: 2 µg/ml. HEK293: 5-Fluorocytidine: 0.0625 µg/ml, 2'-deoxy-5-Fluorocytidine: 0.0156 µg/ml, 5-Fluorouridine: 0.0156 µg/ml, 2'-deoxy-5-Fluorouridine: 0.0156 µg/ml. Data presented is one representative of three independent experiments, which was analysed by Mixed model analysis followed by Dunnett's multiple comparison test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.